ArticleJournal of the Endocrine Society2026
Adherence to daily growth hormone therapy in Japan: real-world data from the Melon Nikki™ app and device.
Article in Journal of the Endocrine Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Context: Since 2020, growth hormone (GH) therapy administered using electronic drug delivery devices (GROWJECTOR Objectives: To assess adherence to home-based GH self-injection using a smartphone application linked to an electronic injection device and identify factors associated with adherence. Design: Observational study. Setting: Real-world data were collected and analyzed, including home injection patterns, GH dosage, and changes in height and body mass index over the first year of therapy. Factors significantly associated with adherence outcomes were evaluated using statistical analyses. Patients: We enrolled a cohort of Japanese pediatric patients with various indications for GH therapy who used an electronic injection device connected to the Melon Nikki Results: Injection adherence declined after the second month in patients with GH deficiency and after the fourth month in patients born small for gestational age, particularly among those with variable injection times. Multivariate analysis showed that cumulative app usage up to 24 weeks is an independent factor that significantly contributes to an increase in the cumulative injection rate. Use of the application was associated with better adherence during initial 8 weeks. Conclusion: Use of a smartphone application linked to an electronic injection device may support adherence maintenance during the early phase of GH therapy. These findings provide clinically relevant insights that may inform patient guidance and adherence-focused interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.